



Advancing Science

in the Pharmaceutical and
Biotechnology Sector

Q4 and FY 2024 Earnings Call | March 4, 2025

Disclaimer

This presentation has been prepared by DRI Healthcare Trust (the "Trust"). The Trust is an unincorporated open-ended trust governed by the laws of the Province of Ontario, Canada and is externally managed by DRI Capital Inc. ("DRI Healthcare"). The Trust completed an initial public offering (the "IPO") on February 11, 2021, in which it acquired an initial portfolio of royalty assets from DRI Healthcare. The predecessor of DRI Healthcare was founded in 1989. Any references to employees or historical figures prior to the IPO refer to those of DRI Healthcare. This document includes information regarding the historical performance of private funds managed by DRI Healthcare, and is not indicative of future results.

Cautionary Note Regarding Forward-Looking Information

This presentation, including responses to questions related thereto, may contain "forward-looking information" within the meaning of, and made pursuant to the "safe harbor" provisions of, Canadian provincial securities laws. Statements that contain forward-looking information are predictive in nature, depend upon or refer to future events or conditions, and include, but are not limited to, statements which reflect management's current opinions, estimates and assumptions regarding the operations, business, investment opportunities, the profitability and availability of royalty investments, results, performance, financial position and compounding of cash flow, expected financial results, priorities, objectives, strategies, prospects, pipeline, capital management and both short- and long-term outlook of the Trust and its subsidiaries, which are based on management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate and reasonable in the circumstances. Statements containing forward-looking information are typically identified by words such as "guidance," "target," "project," "assumes," "seek," "objective," "outlook," "commitment," "believe," "expect," "will," and other similar expressions.

Despite careful consideration and review of the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct, and undue reliance should not be placed on such statements. Forward-looking information is subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results to materially differ from those depicted or implied by such information, including but not limited to the risk factors or assumptions identified in the Trust's most recent Management's Discussion and Analysis ("MD&A"), under "Risk Factors" in the Trust's most recent Annual Information Form, and in the Trust's other filings with Canadian securities regulators available on SEDAR+ at www.sedarplus.ca.

The forward-looking information contained in this presentation represents management's expectations as of the date of this presentation, and are subject to change after such date. Except as may be required by applicable securities laws, the Trust does not undertake any obligation to update or revise any statement containing forward-looking information in this presentation, whether as a result of new information, future events or otherwise.

Non-GAAP Measures and Ratios

This presentation also makes reference to certain non-GAAP financial measures including Total Cash Receipts, Normalized Total Cash Receipts, Total Cash Royalty Receipts and Adjusted EBITDA, and certain non-GAAP ratios including Adjusted EBITDA Margin and Adjusted Cash Earnings per Unit. These measures and ratios are not standardized measures under the International Financial Reporting Standards ("IFRS") and are therefore unlikely to be comparable to similar financial measures disclosed by other issuers. Rather, these measures and ratios are provided as additional information to complement those IFRS measures by providing further understanding of the Trust's financial performance from management's perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of financial information reported under IFRS. See "Financial Review: Non-GAAP Financial Measures" in the MD&A, which includes a reconciliation of IFRS to non-GAAP measures, such reconciliation being incorporated by reference herein.

All dollar figures in this presentation are stated in US dollars.



Gary Collins
Chairman &
Chief Executive Officer

Agenda



Gary Collins
Chairman & CEO

—————> 2024 Highlights



Navin Jacob
CIO, DRI Healthcare

—————> Portfolio Update



Amit Kapur
CFO

—————> Financial Update



Ali Hedayat
Acting CEO, DRI Healthcare

—————> Guidance and Strategy Update

All

Q&A

2024 Highlights

Focus on deal execution, unitholder returns and building alignment



Accretive Transactions

Over \$290 million deployed

- Up to \$457 million in committed capital
- Innovative deal structures that increase portfolio duration and diversification



Governance Enhancements

Internally improved processes

- Trust CEO and CFO are independent of the manager
- Improved internal controls and remediated material weaknesses



Increased Capacity

Significant capital for growth

- Refinanced preferred securities and retired 4.6 million net warrants
- Increased total credit available from credit facilities to \$632 million



Unitholder Value

Distributions and unit buybacks

- \$3.9 million, or 406,346 units, repurchased under NCIB
- \$20.5 million returned via cash and unit distributions

2024 Financial highlights

Normalized Total Cash Receipts¹

\$190.0 million

↑ 45% over 2023

Total Income

\$187.5 million

↑ 13% over 2023

Adjusted EBITDA¹

\$156.6 million

↑ 37% over 2023

Adjusted EBITDA Margin¹

82%

Adjusted Cash Earnings per Unit¹

\$2.18

Declared Cash Distributions per Unit

\$0.340

1. Normalized Total Cash Receipts and Adjusted EBITDA are non-GAAP measures. Adjusted EBITDA Margin and Adjusted Cash Earnings per Unit are non-GAAP ratios. See "Financial Review: Non-GAAP Financial Measures" in our MD&A.






Navin Jacob

Executive Vice President, Investments &
Chief Investment Officer,
DRI Healthcare

Focused on closing accretive transactions

Completed four transactions in 2024 totaling up to \$457 million, with \$290 million deployed to date¹

	INVESTMENT THESIS	TRANSACTION SIZE
	Uncapped transaction on established product providing cash accretion	\$115 million + up to \$55 million in potential milestones
	Only approved product for acid sphingomyelinase deficiency (“ASMD”) with strong IP protection and long duration	\$13.25 million + up to \$32.5 million in potential milestones
	Provides predictable cash flows with potential for upside optionality and limited risk	\$57 million
Sebetralstat	Pre-approval asset with high conviction of approval plus PIPE investment	\$105 million + up to \$79 million in potential milestone and option payments

1. Excludes \$167 million in potential additional milestone and option payments.

Portfolio performance

Portfolio assets show continued growth

(\$ millions)	Q4 2024	Q4 2023	% Change ¹	2024	2023	% Change ¹
TOTAL CASH ROYALTY RECEIPTS²	\$44.6	\$52.3	(15)%	\$190.0	\$127.9	49%
EMPAVELI [®] SYFOVRE [®]	2.0	1.4	37	6.3	1.9	234
EYLEA [®]	1.7	1.8	(2)	6.8	7.6	(10)
FluMist Quadrivalent	-	0.9	(100)	-	2.4	(100)
Natpara [®]	0.4	0.6	(39)	2.1	2.4	(14)
OMIDRIA [®]	8.3	3.3	156	37.7	13.0	190
ORACEA [®]	1.6	2.3	(29)	7.4	8.3	(11)
ORSERDU [®]	13.9	23.2	(40)	65.6	26.6	146
RYDAPT [®]	0.7	1.7	(60)	5.5	8.2	(34)
SPINRAZA [®]	3.7	4.4	(17)	14.7	16.8	(12)
Stelara [®] Simponi [®] ILARIS [®]	0.2	0.3	(32)	0.8	1.3	(39)
VONJO [®]	4.1	3.7	10	19.8	11.2	77
Xenpozyme [®]	0.8	0.4	90	1.5	0.7	119
Xolair [®]	3.5	3.2	11	10.7	9.9	7
Zejula [®]	1.0	0.9	10	3.9	3.1	25
Zytiga [®]	2.5	3.7	(32)	6.0	12.2	(51)
Other Products ³	0.2	0.5	(46)	1.2	2.3	(45)

1. Total % Change columns are based on figures rounded to the thousands and align with the information in our MD&A. 2. Total Cash Royalty Receipts is a non-GAAP financial measure. See "Financial Review: Non-GAAP Financial Measures" in our MD&A. 3. Other Products includes royalty income from certain other royalty assets, as well as royalty assets which are fully amortized and, where applicable, the entitlements to which have generally expired.

DRI HEALTHCARE

Robust pipeline of over
\$3 billion
in potential opportunities¹



Address important unmet needs with life-changing therapies for patients



Marketed by leading biotech or biopharma companies



Provides strong intellectual property and regulatory protection

¹. As of March 4, 2025. Represents the aggregate value of potential opportunities that meet or exceed DRI Healthcare's qualitative and quantitative investment criteria.




Amit Kapur
Chief Financial
Officer

Strong cash generation

Cash available to drive portfolio growth and maintain distributions to unitholders

Adjusted EBITDA for the Last Twelve Months Ended December 31, 2024 (\$M)¹




Adjusted EBITDA Margin¹
82%



Adjusted Cash Earnings per Unit⁴
\$2.18

1. Adjusted EBITDA and Normalized Total Cash Receipts are non-GAAP financial measures. Adjusted EBITDA Margin and Adjusted Cash Earnings per Unit are non-GAAP ratios. Adjusted EBITDA Margin is calculated as Adjusted EBITDA / Normalized Total Cash Receipts. **2.** The Net Change in Royalties Receivable and Interest Receivable represents royalties and interest receivable at the beginning of period, less royalties and interest receivable at the end of period, plus acquired royalties receivable included in the purchase price of the assets, less other interest income and less prepayment premium income on loan receivable. **3.** Operating expenses are net of \$0.4 million related to board of trustee unit-based compensation. **4.** Adjusted Cash Earnings per Unit is calculated as comprehensive earnings (loss), plus: (i) amortization of royalty assets, (ii) amortization of other current assets, (iii) impairment of royalty assets, (iv) unit-based compensation, (v) board of trustees unit-based compensation, (vi) management and performance fees on sale of royalty asset and (vii) other loss, less: (i) non-cash royalty income, (ii) non-cash interest and other income on loan receivable, (iii) prepayment premium income on loan receivable, (iv) net gain on sale of royalty assets, (v) net gain on debt refinancing, (vi) net unrealized gain on derivative instruments and (vii) net unrealized loss on marketable securities; divided by weighted average units outstanding.

Well capitalized for growth



Significant
capacity for
further
growth

2024 Guidance Lookback

Announced on
Feb 28, 2024


After
Feb 2024



2024 royalty
income guidance

\$153-155
million

Excluding milestone income
and any new transactions



1. Composed of \$184.7 million of Royalty Income less \$18.2 million of royalty exemptions on Orserdu royalties and milestones (see "Key Developments Related to our Assets" in our MD&A) and \$0.9 million of royalty income from Xenpозyme II, which was executed subsequent to February 28, 2024. 2. Includes \$18.2 million of royalty exemptions on Orserdu royalties. 3. Includes Royalty Income from Xenpозyme II and the change in fair value of financial royalty assets from Casgevу, both of which were completed subsequent to February 28, 2024. 4. Equals Total Income less Other Interest Income.



Ali Hedayat

Acting Chief Executive Officer
DRI Healthcare

Updated guidance

Focus on sustainable strategic growth

	2024 GUIDANCE	2025 GUIDANCE
Capital deployment target	More than \$1.25 billion over 5 years from IPO ¹	More than \$1.25 billion over 5 years from IPO¹
Income from royalty assets	\$153 – 155 million ²	\$172 – 182 million²
Sustainable cash generation	Mid- to high-single digit royalty income CAGR through 2030 ³	High-single digit royalty income CAGR through 2030³

1. Statements regarding the Trust's outlook over 5 years are based on its most up-to-date view of its prospects as of the date of this presentation. This long-term outlook includes potential royalty transactions currently in the Trust's pipeline and future royalty transactions that it may bring into its pipeline in accordance with its strict investment criteria. This long-term outlook assumes no material adverse events following the date of this presentation. 2. Includes Royalty Income plus the change in fair value of financial royalty assets, excluding milestones and any new transactions. 3. Includes Royalty Income plus the change in fair value of financial royalty assets, excluding any new transactions.

DRI HEALTHCARE

Key
priorities



Rebuild trust with a focus on strong governance and tone from the top



Invest in our people and build the industry leading royalty investment team



Execute on strong pipeline and operate at peak performance



Focus on long-term, sustainable growth generating strong unitholder returns